Does Blue Cross Cover Wegovy in 2026? BCBS Coverage by State

Wegovy fares better than any other weight-loss injection on Blue Cross plans in 2026, partly because several Blues' pharmacy managers made it their preferred GLP-1. The state-by-state structure still means your card decides.

Many Blue Cross Blue Shield plans cover Wegovy in 2026 with prior authorization requiring a BMI of 30 or higher, or 27 or higher with a weight-related condition, and Wegovy frequently holds preferred status over Zepbound on Caremark-managed Blues. The restrictions wave hit here too: Blues in Michigan and Massachusetts cut weight-loss GLP-1 coverage for fully insured plans in 2026, though Wegovy's separate FDA approval for cardiovascular risk reduction keeps a disease-treatment route open on most plans for heart patients.

Below: where Wegovy stands across the Blues, the criteria, the heart pathway, and current costs.

Wegovy's Position Across the Blue System

The Blue Cross Blue Shield Association's 33 independent companies set their own formularies, but Wegovy benefits from two tailwinds. First, on Blues whose pharmacy benefits run through CVS Caremark, the July 2025 Novo Nordisk deal made Wegovy the preferred weight-loss GLP-1 with Zepbound excluded. Second, even Prime Therapeutics and Express Scripts Blues that list both drugs frequently order step therapy with Wegovy first, making it the path of least paperwork.

The 2026 restriction wave still applies where it applies. Fully insured members of Blues that dropped the weight-management category (Michigan's January 2026 change is the most prominent) lost Wegovy along with the rest of the class. Self-funded employer plans choose independently and many retained it. Anthem-affiliated Blues across 14 states broadly maintained coverage with tightened criteria.

The Cardiovascular Route Most Blue Members Don't Know About

Wegovy holds an approval no other weight-loss drug had first: the FDA's March 2024 indication for reducing cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight.

That label treats heart disease, not weight, which changes the coverage analysis on plans that exclude anti-obesity drugs. If you have a documented prior heart attack, stroke, or peripheral arterial disease and a BMI of 27 or higher, your prescriber can submit under the cardiovascular indication with your cardiac records attached. Most Blues evaluate these requests outside the weight-loss exclusion, and it's the standard Wegovy route on Blue-affiliated Medicare Advantage plans today.

Standard Criteria and What Approval Takes

Where the weight-management benefit exists, the criteria track the FDA label: BMI 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, prediabetes, dyslipidemia, or sleep apnea. Most Blues add lifestyle-program documentation (commonly 3 to 6 months) and renewals requiring at least 5 percent weight loss from baseline.

Submission strategy matters. Have your prescriber attach baseline BMI, comorbidity documentation, and program notes to the first request; complete files clear within 72 hours while incomplete ones generate the denials that fill appeal queues. Calendar the renewal date and keep weigh-ins in your chart so the continuation request writes itself.

What Wegovy Costs on Blue Cross in 2026

Covered copays span $25 to $200 monthly across Blue plan designs, with several Blues adopting flat $200 weight-management copay structures in 2026 that sit outside out-of-pocket maximums. Novo Nordisk's savings card cuts eligible commercial copays by up to $100 monthly and stacks with most Blue designs.

Without coverage, the self-pay ladder runs: NovoCare Pharmacy and major retailers at about $499 monthly, the federal TrumpRx channel near $350 for semaglutide as it phases in, and list price around $1,350 that no one should pay. Medicare-eligible members get the $50 copay cap, via the cardiovascular route now or the GLP-1 Bridge pilot for weight management starting July 1, 2026.